Siltuximab:
Palanques-Pastor et al suggested the administration of this drug to treat severe SARS CoV-2 infection. This can be achieved due to its interference with IL 6, which in turn leads to decrease binding with its receptors; thus, hyperinflammatory response due to cytokine storm is inhibited. Its half-life suggests that a single intravenous dose can be infused. It is generally well-tolerated, but complete blood count should be done before drug administration. [40]